BioSpace News Archive

According to Nova one advisor’s recent analyses the global Life Science Instrumentation market size is expected to hit USD 106.5 billion by 2030 from at USD 57.6 billion in 2022 and is expanding growth at a noteworthy CAGR of 6.27% from 2022 to 2030.

OKYO Pharma Limited announced that it filed an Investigational New Drug application with the U.S. Food and Drug Administration for the development of OK-101 to treat dry eye disease.

The board of directors of the Company is pleased to announce that in order to meet the rapidly growing market demand for HPV 9-valent vaccines in China and the international market, after process optimization, facility upgrading and verification, the peak production capacity for the first phase of the HPV vaccine manufacturing facility of the Company will be increased to an annual output of 20 million doses of recombinant HPV 9-valent vaccine.

Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced that Pia Baumann has been recruited as its new Chief Medical Officer.

Taking anti-inflammatory pain relievers like ibuprofen and naproxen for osteoarthritis may worsen inflammation in the knee joint over time, according to a new study being presented next week at the annual meeting of the Radiological Society of North America.

Cambrex today announced that it has entered into a definitive agreement to acquire Snapdragon Chemistry, a leading US-based provider of chemical process development services to a broad range of emerging and established biopharma customers.

Teleflex Incorporated today has announced it was named a MedReps.com 2023 Best Places to Work, earning the Number 1 spot for large companies and making this the sixth consecutive year the company has been on the list.

Replay, a genome writing company reprogramming biology by writing and delivering big DNA, today announced the launch of Telaria, a HSV gene therapy company targeting rare skin diseases.

Athira Pharma, Inc. today announced that additional biomarker data from the completed, exploratory ACT-AD Phase 2 study of fosgonimeton (ATH-1017) in patients with mild-to-moderate Alzheimer’s disease was selected as a late-breaking poster presentation at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference, taking place November 29 - December 2, 2022, in San Francisco, California and virtually.

TELA Bio, Inc. today announced that the Company will participate in the Piper Sandler 34th Annual Healthcare Conference on November 30th , 2022.